Management

Zoltan Kiss, Ph.D. - He founded Visceral Fat Control biotechnological company in 2020 for which now he serves as the President and CEO. This family-owned company is based, for the most part, on his extensive research showing that two human proteins, used either in highly purified or recombinant form, can specifically normalize excess visceral (abdominal) fat in appropriate animal models without significantly affecting general obesity. The company hopes to apply one of these proteins (ZKPr1) to treat excess visceral fat in both non-obese and obese people.

*About the Founder: Zoltan Kiss, Ph.D., had an extensive academic research career before founding and leading several biotechnological companies. Until 2004, he was Professor and Section Leader at the University of Minnesota. Prior to that, he was a Senior Investigator at the National Cancer Institute (4 years) and held several faculty positions in the U.S. and Europe. Dr. Kiss holds a Ph.D. degree, and his research so far has resulted in 114 peer-reviewed articles and 27 issued international patents as well as 5 filed patent applications on the treatments of cancer cachexia, wounds, and various metabolic disorders including specific treatment of excess visceral fat. All his issued patents are now owned by MNPHARM, LLP, a Minnesota biotech company. Most recently, Dr. Kiss has been focusing on (1) finding effective interventions to normalize excess visceral obesity and determining the nature of relationships between visceral fat and various metabolic disorders in appropriate mouse models using the ZKPr1 and ZKPr2 nontoxic human proteins, (2) methods to prevent cancer cachexia, and (3) using organic compounds to stabilize body weight for periods when treatments with weight loss drugs are stopped.